News

A first-in class antibody, lenzilumab  binds to and neutralises granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a key cytokine that causes a hyperinflammatory cascade or cytokine storm associated to

The Phase 2, two-arm, randomised, double blind, placebo controlled, multicentre study will evaluate the efficacy and safety of Ampligen in 80 subjects suffering with PCCD. This trial will

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults. Referred to as EnGeneIC Dream Vector (EDV), the

Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.

The European Medicines Agency (EMA) has started evaluation of the data on a booster (third) dose for the Covid-19 vaccine, Comirnaty, developed by Pfizer and BioNTech. The move

This trial will evaluate the safety, tolerability and immunogenicity of Reliance’s vaccine against Covid-19 infection in healthy subjects. The trial will also analyse the maximum tolerated dose of

The US Food and Drug Administration (FDA) has granted fast track designation for Novartis’ agonist LNA043 to treat knee osteoarthritis. LNA043, which has been discovered within the Novartis

Swedish Orphan Biovitrum (Sobi) has agreed a $8bn (SEK69.4bn) takeover offer from Advent International and Singapore’s wealth fund GIC. Sobi’s board of directors had unanimously recommended that shareholders

Moderna has initiated its submission process for the evaluation of a booster dose of its Covid-19 vaccine at the 50µg dose level, to the US Food and Drug